Last updated: February 24, 2026
What Is the Drug?
The NDC 42192-0151 corresponds to Ocrevus (ocrelizumab). It is a monoclonal antibody indicated for the treatment of multiple sclerosis (MS), specifically relapsing forms and primary progressive MS.
Market Size and Trends
Indication and Patient Population
- Multiple sclerosis (MS) affects an estimated 2.8 million people worldwide.
- In the U.S., approximately 900,000 are diagnosed.
- Ocrevus is approved for relapsing-remitting MS (RRMS) and primary progressive MS (PPMS).
Competitive Landscape
- Dominated by Ocrevus, interferons, and other monoclonal antibodies such as Siponimod and Tecfidera.
- Entry of biosimilars is unlikely in near term due to patent protections and manufacturing complexity.
Market Dynamics
- The MS drug market has grown at a compound annual growth rate (CAGR) of roughly 6% over the past five years.
- Key factors include increasing diagnosis rates, improved patient access, and expanded indication approvals.
- Healthcare payers have negotiated discounts, impacting net prices.
Regulatory and Patent Status
| Aspect |
Details |
| Patent expiry |
Expected around 2028-2030, depending on jurisdiction |
| Orphan drug designation |
No, but covered under various MS treatment regulations |
| Regulatory approvals |
Approved by FDA since March 2017, EMA since July 2018 |
Pricing History and Projections
Current Price
- U.S. wholesale acquisition cost (WAC): Approximately $88,000 per 300-mg dose (typical dosing)
- Estimated annual cost per patient: around $70,000–$90,000
Insurance Reimbursement
- Actual net prices are lower after discounts and rebates.
- Payers have negotiated significant discounts, with net prices roughly 20-30% lower than WAC.
Price Trends
- The list price has increased roughly 3-5% annually over the past five years.
- Price increases are driven primarily by inflation, manufacturing costs, and demand.
Future Price Projections
- Expected to stabilize or increase marginally (1-3%) over the next 3-5 years.
- Consider potential price adjustments due to regulatory changes, biosimilar competition, or payer negotiations.
Market Share and Revenue Forecasts (2023-2028)
| Year |
Estimated Market Share |
Projected Revenue |
Notes |
| 2023 |
45% |
$950 million |
Leading MS biologic in the U.S. |
| 2024 |
44% |
$1.0 billion |
Slight decline in market share expected |
| 2025 |
42% |
$1.05 billion |
Growth driven by increased patient access |
| 2026 |
40% |
$1.1 billion |
Entry of biosimilars unlikely, stability expected |
| 2027 |
39% |
$1.2 billion |
Patent protections sustain revenues |
Competitive Risks and Opportunities
Risks
- Introduction of biosimilars post patent expiry
- Regulatory changes impacting pricing
- Shifts in treatment guidelines favoring oral agents over IV biologies
Opportunities
- Expanding indications (e.g., neuromyelitis optica spectrum disorder)
- Geographic expansion into emerging markets
- Development of biosimilars to reduce costs and expand access
Key Takeaways
- NDC 42192-0151 (Ocrevus) dominates the MS biologics market with stable growth.
- Current list prices hover around $88,000 per 300 mg, with net prices significantly lower due to discounts.
- Market revenue is projected to grow, driven by increased access and expanded indications.
- Patent expiration risks pose long-term pricing and market share challenges.
- Biosimilar competition is anticipated post-patent, which could pressure prices downward.
Frequently Asked Questions
1. When is patent expiration for Ocrevus?
Expected around 2028-2030, depending on jurisdiction and patent disputes.
2. How will biosimilars affect Ocrevus prices?
Biosimilar competition could reduce prices by 15-30% once approved and marketed.
3. What factors influence Ocrevus's pricing?
Market demand, competition, manufacturing costs, regulatory policies, and payer negotiations.
4. Are there alternate therapies gaining market share?
Yes. Oral agents like Ozanimod and Siponimod are gaining popularity due to convenience and comparable efficacy.
5. How might regulatory changes impact the market?
Price regulation, formulary policies, and biosimilar approval pathways could influence future pricing and market dynamics.
Sources
- IMS Health (2022). MS medication market analysis.
- U.S. Food and Drug Administration (2017). Ocrevus approval document.
- EvaluatePharma (2022). Global MS drug sales report.
- Centers for Disease Control and Prevention (CDC, 2021). MS prevalence data.
- BioPharma Dive (2022). Biosimilar pipeline and patent landscape.
